SMARCA4 and cardiac hypertrophy: Genetic interventions targeting Brg1 have yielded beneficial outcomes, including the attenuation of myocardial hypertrophy, reduced neutrophil recruitment, and improved myocardial ischemia-reperfusion outcomes in animal models (Hang et al., 2010; Shao et al., 2020).